Pharmacosmos Group To Acquire G1 Therapeutics, G1's Shareholders To Receive $7.15 Per Share In Cash For A Total Equity Value Of Approximately $405M
Portfolio Pulse from Benzinga Newsdesk
Pharmacosmos Group is set to acquire G1 Therapeutics, with G1's shareholders receiving $7.15 per share in cash, valuing the total equity at approximately $405 million.
August 07, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharmacosmos Group is acquiring G1 Therapeutics for $7.15 per share in cash, valuing the total equity at approximately $405 million. This acquisition is likely to positively impact G1 Therapeutics' stock price in the short term as shareholders will receive a premium.
The acquisition price of $7.15 per share represents a premium over the current trading price of G1 Therapeutics, which is likely to drive the stock price up in the short term as investors react to the news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100